{"id":6773,"date":"2021-09-27T11:42:39","date_gmt":"2021-09-27T10:42:39","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/?post_type=webcast&p=6773"},"modified":"2025-10-11T14:43:17","modified_gmt":"2025-10-11T12:43:17","slug":"next-generation-btk-inhibitors-for-relapsed-refractory-b-cell-malignancies-what-are-the-options-and-how-do-they-compare","status":"publish","type":"webcast","link":"https:\/\/beonemedaffairs.com\/begenius\/webcast\/6773\/next-generation-btk-inhibitors-for-relapsed-refractory-b-cell-malignancies-what-are-the-options-and-how-do-they-compare\/","title":{"rendered":"Next-generation BTK inhibitors for relapsed\/refractory B-cell malignancies: What are the options and how do they compare?"},"content":{"rendered":"","protected":false},"template":"","class_list":["post-6773","webcast","type-webcast","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/webcast\/6773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/webcast"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/types\/webcast"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/begenius\/wp-json\/wp\/v2\/media?parent=6773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}